# The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

> **NCT05078255** · NA · COMPLETED · sponsor: **Asger Lund, MD** · enrollment: 61 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity

## Interventions

- **DRUG:** Semaglutide 1.34 MG/ML [Ozempic]
- **DRUG:** Glucose-dependent insulinotropic polypeptide (GIP)
- **OTHER:** Semaglutide 1.34 mg/ml placebo
- **OTHER:** GIP placebo

## Key facts

- **NCT ID:** NCT05078255
- **Lead sponsor:** Asger Lund, MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-27
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-01-24
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05078255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05078255, "The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05078255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*